Clinical trial
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene…
NCT03769116 · Sarepta Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT03769116 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001 |
| Lead sponsor | Sarepta Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Muscular Dystrophy, Duchenne |
| Intervention type | Genetic |
| Interventions | delandistrogene moxeparvovec, placebo |
| Enrollment | 41 |
| Start date | Dec 5, 2018 |
| Primary completion | Dec 8, 2020 |
| Completion | Aug 16, 2023 |
| First posted | Dec 7, 2018 |
| Last update posted | Nov 14, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: